Polonia Jorge, Azevedo André, Monte Miguel, Silva José A, Bertoquini Susana
Department of Medicine, CINTESIS, Faculty of Medicine of Porto, University of Porto, Porto, Portugal.
Blood Pressure Unit, Hospital Pedro Hispano, Matosinhos, Portugal.
Vasc Health Risk Manag. 2017 Jun 26;13:231-237. doi: 10.2147/VHRM.S135253. eCollection 2017.
Chronic kidney disease (CKD) complicates hypertension and diabetes. Knowledge of the deterioration rate of CKD may anticipate adjustment of therapies with renal elimination. This study evaluates the rate of annual deterioration of renal function in hypertensive patients either with type 2 diabetes (DM2) or without it (non-DM) followed for 5 years and relates it with blood pressure (BP) and glycemic control.
Out of a total of 1924 patients, 1023 patients (594 non-DM and 429 DM2, 53% female, aged 62.1±10.2 years) were evaluated over 5 years for the annual evolution of renal function (estimated glomerular filtration rate [eGFR], Modification of Diet in Renal Disease) ambulatory 24-hour blood pressure and metabolic parameters, corresponding to the analysis of 2378 patient-years.
DM2 and non-DM did not differ for age, mean 24-hour BP levels, nighttime BP, albuminuria, and body mass index. DM2 versus non-DM showed a higher (<0.02) prevalence of stage 3 CKD (24.0% vs 18.0%, eGFR 30-59), stage 4 (5.4% vs 2.7%, eGFR 15-29), and stage 5 (0.8% vs 0.5%, eGFR <15). Average annual decline of eGFR was 3.3±8.2 in DM2 versus 2.4±7.7 in non-DM (=0.12, nonsignificant). Annual changes of eGFR and of albuminuria correlated (=0.578, <0.001). In multivariate analysis, age, nighttime BP, double inhibition of renin angiotensin system, albuminuria, and HbA1c >8.0% in DM2 predicted the decline in eGFR. On average, 16.2% of DM2 and 13.1% of non-DM moved each year toward a more severe stage of CKD. For initial eGFR <90 mL/min/1.73 m, 26.4% of DM2 and 18.1% of non-DM patients showed a reduction per year >10% from the previous eGFR value (=0.042).
Progressive deterioration of renal function each year is frequent in hypertensive diabetic and non-diabetic patients. Beyond aging, this is particularly dependent on BP control particularly at nighttime, on drug therapy, and on highly abnormal glucose control.
慢性肾脏病(CKD)使高血压和糖尿病病情复杂化。了解CKD的恶化速率有助于预期调整肾脏排泄相关的治疗方案。本研究评估了随访5年的2型糖尿病(DM2)高血压患者和非糖尿病(非DM)高血压患者的肾功能年恶化速率,并将其与血压(BP)和血糖控制情况相关联。
在总共1924例患者中,对1023例患者(594例非DM和429例DM2,女性占53%,年龄62.1±10.2岁)进行了5年的肾功能(估算肾小球滤过率[eGFR],肾脏病饮食改良法)、动态24小时血压及代谢参数年度变化评估,相当于对2378患者-年进行分析。
DM2组和非DM组在年龄、平均24小时血压水平、夜间血压、蛋白尿及体重指数方面无差异。DM2组与非DM组相比,3期CKD(eGFR 30 - 59)、4期(eGFR 15 - 29)和5期(eGFR <15)的患病率更高(<0.02)(分别为24.0%对18.0%、5.4%对2.7%、0.8%对0.5%)。DM2组eGFR的平均年下降率为3.3±8.2,非DM组为2.4±7.7(P = 0.12,无统计学意义)。eGFR和蛋白尿的年度变化具有相关性(P = 0.578,<0.001)。多因素分析显示,年龄、夜间血压、肾素血管紧张素系统双重抑制、蛋白尿以及DM2组糖化血红蛋白>8.0%可预测eGFR下降。平均而言,每年有16.2%的DM2患者和13.1%的非DM患者向更严重的CKD阶段进展。对于初始eGFR<90 mL/min/1.73 m²的患者,26.4%的DM2患者和18.1%的非DM患者每年eGFR较上一年下降>10%(P = 0.042)。
高血压糖尿病患者和非糖尿病患者每年肾功能都会频繁出现进行性恶化。除衰老外,这尤其取决于血压控制,特别是夜间血压控制、药物治疗以及血糖控制严重异常。